Singapore: Akebia Therapeutics and Mitsubishi Tanabe Pharma Corporation (MTPC)has announced that they have entered into a development and commercialization agreement for vadadustat (formerly AKB-6548), an oral therapy for the treatment of anemia related to chronic kidney disease (CKD), in Japan and certain other countries in Asia.. Under the terms of the agreement, MTPC will make payments ....